Navigation Links
Hormonal male contraception reversible after few months for all men

With hormonal male contraception likely to be available in the near future, results of a study in this week's issue of THE LANCET highlight how such contraception is reversible within a few months.

Currently available male contraceptive methods (condoms, withdrawal, and vasectomy) are not acceptable to many couples because they are either not sufficiently reliable or not easily reversible. In a similar way to ovulation suppression by hormone treatment in women, sperm production can be fully inhibited by androgen or androgen-progestagen treatment combinations in men. With such hormone treatment, azoospermia (no sperm in ejaculate) or severe oligozoospermia (less than 3 million sperm per mL of semen), which is sufficient for contraceptive purposes, can be achieved. Currently, a large phase III study with an androgen treatment and a large, multicentre phase II study of androgen-progestagen combinations are being completed in China and Europe, respectively.

Peter Liu from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), who is currently located at the ANZAC Research Institute, University of Sydney, Australia, and colleagues analysed data from individual participants in 30 studies published in 1990?005, in which sperm output was monitored every month until recovery. The primary outcome was the time for the sperm concentration to recover to a threshold of 20 million per mL, an indicator of fertility.

Data were available for around 1500 men. The average time for sperm recovery to 20 million/mL was 3? months. Various factors were associated with higher rates of recovery including older age, Asian origin, shorter treatment duration, and higher sperm concentrations at baseline. Although these factors modulated the speed of recovery, spermatogenesis recovered to levels compatible with fertility in all men.

Dr Liu and colleagues comment: "Our data provide strong assurance that the previously described eff
'"/>

Source:Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)


Page: 1 2

Related biology news :

1. Emergency contraception fails to halt abortions
2. Male contraception: One door opens, another closes
3. Cancer cells suppress large regions of DNA by a reversible process that can be tackled
4. Rewind, please: Nature paper shows that cell division is reversible
5. First-degree fetal heart block may be reversible
6. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
7. Does vitamin C help prevent or treat the common cold? Maybe not, after all.
8. Stem cell treatment improves mobility after spinal cord injury
9. Bad aftertaste? New sensory on/off switch may cure bane of artificial sweetener search
10. New type of rejection blocker protects kidneys after transplant
11. Hurricane aftermath: Infectious disease threats from common, not exotic, diseases
Post Your Comments:
(Date:12/14/2009)... (INTA-CSIC) has shown that hydrogen cyanide, urea and other ... basic biological molecules can be obtained from the salt ... published in the journal Chemistry & Biodiversity , ... Earth. , "We have shown that when Prussian blue ... a substance that could have played a fundamental role ...
(Date:12/14/2009)... As good as laparoscopy is in preventing some of ... have drawbacks, including reduced blood flow and organ dysfunction. Laparoscopy ... small incisions. , By adding another ... area during laparoscopy, researchers at Duke University Medical Center have ... surgery. , The gas ethyl nitrite (ENO) helped to ...
(Date:12/13/2009)... that are associated with the health of the human ... scientists from 63 centres in Europe and Australia sheds ... , The new findings provide hope for better treatment ... and asthma. In the past it has been difficult ... affect the health of the lung are not completely ...
Breaking Biology News(10 mins):Prussian blue linked to the origin of life 2Gas improves blood flow and organ status during minimally invasive surgery 2New genes for lung disease discovered 2Good Samaritan Hospital Dayton Rated 231 in Ohio for Vascular Surgery 3B 231 in Dayton for Joint Replacement 59367 1Good Samaritan Hospital Dayton Rated 231 in Ohio for Vascular Surgery 3B 231 in Dayton for Joint Replacement 59367 2Good Samaritan Hospital Dayton Rated 231 in Ohio for Vascular Surgery 3B 231 in Dayton for Joint Replacement 59367 3New Palliative Medicine Hotline Reaches California 59363 1New Palliative Medicine Hotline Reaches California 59363 2New Palliative Medicine Hotline Reaches California 59363 3Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 14449 1Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 14449 2
... of adults aged 20 and over, researchers at Tufts University ... levels in individuals who have a combination of vitamin B12 ... are also vitamin B12 deficient but have normal folate levels. ... enzymes that contain vitamin B12, accumulate in the blood in ...
... laboratory tool for measuring pharmacological activity of biological substances ... by a new miniaturized bioassay that will be faster, ... new technology developed by Singapores Institute of Bioengineering and ... DropArray, slashes the time needed to run certain lab ...
... muscle. Sometimes one sudden, inconsiderate movement does the job. ... as other tissues such as bone. Researchers of the ... and the Harefield Heart Science Centre of Imperial College ... muscle regenerate and protects it from atrophy. In this ...
Other Biology News:Vitamin B-12 function may be diminished by excessive folate 2Cheaper drugs now closer to realization with new DropArray technology 2Cheaper drugs now closer to realization with new DropArray technology 3An ambulance man for muscle damage 2
(Date:12/14/2009)... with State Biotech Leaders to Develop Blueprint ... Development while Boosting Rhode Island,s Growing Biotech ... R.I., Dec. 14 Several of ... medicine and biotechnology gathered today at Brown ... importance of medical innovation in Rhode Island ...
(Date:12/14/2009)... -- Lionbridge (Nasdaq: LIOX ) today ... three-year master services agreement with a multi-billion ... that serve patients in approximately 100 countries. ... sole provider for translation of the company,s ... human resources, legal, and corporate communications information. ...
(Date:12/14/2009)... delivery of Brookfield Engineering’s Powder Flow Tester – helping Brookfield ... smaller footprint and more compact design. , ... ... a US-based thermoforming company, has completed the delivery of Brookfield ... metal to a plastic enclosure with a smaller footprint and ...
(Date:12/11/2009)... Corporation (Nasdaq: DNDN ) announced today that ... have exercised in full their option to purchase ... the public offering price of $24.75 per share. ... size of the offering to an aggregate of ... to receive net proceeds from the offering of ...
Breaking Biology Technology:Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 2Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
... human immune system isnt ready for a war. , ... illness, but they take time to work. A new ... Foundation (OMRF) and Emory University stands to revolutionize the ... Nature, the researchers describe a method that can identify ...
... active first quarter 2008 stock ... repurchase program, BOSTON, April ... medical image and information management,solutions, today reported unaudited financial results for the ... ), Q1 Financial Highlights, Revenue: Total revenues for ...
... a New Step in the Company,s Global Branding ... (Nasdaq:,SIAL) today announced the full integration of its ... effective May 1, 2008,( http://www.sigma-aldrich.com/rebranding )., "We ... products and,services," said Josef Zihlmann, Global Vice President ...
Other Biology Technology:The most natural drug 2AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 2AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 3AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 4AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 5AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 6AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 7AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 8AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 9AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 10AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 11Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 2Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 3
... Polyclonal Antibody Description: ... polyclonal antibody. Detects 70 kDa YAP ... blotting and immunohistochemistry. ... Storage: -20C ...
...
... Mammalian Protein Extraction Reagent is ... solution that means no scraping, ... sonication! With M-PER Reagent, rapid ... minutes at room temperature, yielding ...
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
Biology Products: